Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Amgen Pauses Some Clinical Trials to Reduce Coronavirus Transmission Risk


In their efforts to reduce the chances of people being exposed to COVID-19, a growing number of medical centers around the globe have started restricting nonessential visits, including those necessary to conduct clinical drug trials.

In light of that, and to avoid unnecessary risks, biotechnology giant Amgen (NASDAQ: AMGN) recently decided to pause enrollment and screening of clinical trials wherever safety and data integrity could become an issue. 

In a recent update regarding its COVID-19 pandemic strategy, Amgen outlined the basic principles that will guide its drug development activity over the next several months. Studies of treatments that could provide evidence of a life-saving benefit to patients who lack other options will continue as long as registered trial sites can safely enroll and monitor patients. 

Continue reading


Source Fool.com

Like: 0
Share

Comments